MeMed

18/05/2026

📃 New real-world evidence: implementing in routine led to meaningful improvements in both antibiotic use and hospital length of stay.

A pragmatic pre-/post-implementation study (n=1,496) published in Frontiers in Pediatrics found that when MeMed BV results were available in time to inform clinical decisions:

✔️ 63% fewer antibiotics in outpatients with viral results
✔️ 16% reduction in antibiotic prescribing for lower respiratory tract infections
✔️ Shorter hospital length of stay (3.1 vs. 3.6 days; p < 0.001)

Real-world data from nearly 1,500 patients. One consistent signal: timely, host-response diagnostics optimize care.

📄 Full publication below 👇
https://lnkd.in/d8BTN5_G

25/03/2026

🌎 MeMed Expands Global Footprint with Health Canada Approval of MeMed BV® on MeMed Key®

We’re proud to share that Health Canada has granted approval for on the MeMed Key platform- expanding access to rapid host-response diagnostics across Canada.

With contributing significantly to mortality and antimicrobial resistance on the rise, timely and accurate diagnosis is more critical than ever. MeMed BV helps clinicians distinguish between bacterial and viral infections in just 15 minutes, supporting better treatment decisions when it matters most.

By combining the Diasorin ® platform with the rapid MeMed Key, this enables a hub-and-spoke model connecting central labs with frontline care- expanding access and impact across Canada.



Read more:
https://www.me-med.com/press_release/memed-expands-global-footprint-as-health-canada-approves-memed-bv-on-memed-key/

11/03/2026

🚀 FDA Grants Breakthrough Device Designation to MeMed BV Flex™

MeMed is proud to share that ™ has received FDA Breakthrough Device Designation (BDD), recognizing its potential to transform infection management at the point of care.

MeMed BV Flex uses just a few drops of capillary blood to deliver a clinically actionable score in 15 minutes- leveraging machine learning and multiplex host-response technology to bring lab-grade insights closer to the patient.

The designation enables prioritized FDA engagement and may support a streamlined path to clearance and Medicare reimbursement, helping accelerate access for patients-especially elderly and pediatric populations.

MeMed BV Flex also expands the MeMed Key™ platform, extending high-quality host-response diagnostics across hospitals and decentralized care settings.

**MeMed BV Flex™ is an investigational device and has not been approved or cleared for sale by any regulatory authority.



https://www.me-med.com/press_release/fda-grants-breakthrough-device-designation-to-memed-bv-flex-capillary-blood/

12/01/2026

📢 This just in: MeMed has been awarded a $2 million national grant from the to establish a first-of-its-kind acute care digital and physical biobank.

Selected through a highly competitive national process, will lead the establishment of an acute care diagnostics and proteomics biobank as part of a nationwide AI R&D data infrastructure.

Built on MeMed’s host-response technology, this initiative supports clinicians facing the most urgent, high-stakes decisions in medicine- where minutes matter and biological insight is often missing. By capturing immune biology at the point of care and unifying it with clinical data and AI, the biobank will accelerate the development of next-generation ™ diagnostics for high-risk patients.

Thank you to the Israel Innovation Authority for supporting innovation at the front lines of care. We’re proud to lead this national effort and to help accelerate acute-care innovation by years and millions of dollars.

Read the full press release 👉https://www.prnewswire.com/news-releases/memed-awarded-2-million-grant-to-establish-a-first-of-its-kind-acute-care-digital-and-physical-biobank-302658290.html?tc=eml_cleartime

12/01/2026

23/12/2025

As the year draws to a close, we reflect with gratitude on the passion and dedication of our partners, healthcare professionals, and team members who help advance patient care worldwide every day.
Happy Holidays from all of us at MeMed ✨

22/12/2025

📢 More evidence from pediatric urgent care settings is in: continues to demonstrate meaningful clinical impact in real-world care.

Diagnosing acute infections in children at urgent care centers is often challenging. Physicians must decide, often under timely pressure, whether to prescribe antibiotics or refer a child to the ED, frequently with incomplete or ambiguous clinical information. Having a reliable tool to support these decisions can make a real difference for patients, families, and the healthcare system.

A new pragmatic, real-world study evaluated the use of in pediatric urgent care centers when physicians faced diagnostic uncertainty. The findings highlight MeMed BV’s ability to safely guide decision-making:

✔️ 26% discouraged ED referrals
✔️ 81% physician adherence to MeMed BV result
✔️ 82% physicians reported MeMed BV changed or supported their prescribing decision
✔️ 62% fewer unnecessary antibiotics for viral infections
✔️ 77 % treated appropriately when bacterial infection detected
✔️ Highest impact vs. other biomarkers on antibiotic prescribing (OR 0.07)

Together, these results add yet another layer of evidence from pediatric urgent care settings, showing how MeMed BV supported safe and confident clinical decision-making for pediatric acute infections in urgent care settings.

Full publication here 👇

10.1542/6378834658112Video AbstractPEDS-VA_2024-0699616378834658112OBJECTIVE. Evaluate impact of MeMed BV (MMBV) host-protein test on clinical decision-making for children with acute infection in urgent care centers (UCCs).METHODS. Pragmatic study examining real-world use of MMBV by physicians train...

10/12/2025

A Key Milestone Toward Next Generation ™, Capillary Blood and Venous Blood Equivalency is confirmed!
Our next generation will be moving closer to patients, and we are proud to share a new milestone.
Recent data show that capillary blood samples deliver MeMed BV scores and biomarker values comparable to venous samples.
This achievement has the potential to bring MeMed BV one step closer to broader bedside use. It opens a path for simpler sampling workflows that can support clinical teams in delivering faster and more accessible host response testing.

*MeMed BV Flex is an investigational device, and has not been approved for sale by any regulatory authority.

https://www.sciencedirect.com/science/article/pii/S0009912025001948?dgcid=authorf

01/12/2025

📣 New evidence is in: continues to show high accuracy in some of the most challenging patient populations. This time in hospitalized children.

Managing infections in pediatric wards is complex. Once children are admitted, their symptoms can evolve, presentations blur, and determining if antibiotic treatment for a suspected infection becomes even more challenging. Reliable tools to support this important decision at this stage are essential.

A new study from Wilhelmina Children’s Hospital evaluated MeMed BV's performance on a large cohort of 1,059 hospitalized children. The results speaks for themselves:

• AUC: 0.92
• Sensitivity: 87%
• Specificity: 90%
• NPV: 94 %

Just months after the strong results published in elderly adults, this pediatric inpatient study adds another data point to a growing pattern of consistent performance across complex groups.
Read the full publication below👇

https://journals.lww.com/pidj/abstract/9900/diagnostic_accuracy_of_a_bacterial_versus_viral.1523.aspx

26/11/2025

🦃 Warm Thanksgiving Wishes from MeMed! 🍁

This season, we’re especially thankful for the trust placed in us to help guide care for thousands of patients each year. Every test is a reminder of our mission to advance diagnostics and support better health for all.

Here’s to another year of innovation, collaboration, and shared success! 🍂🥂